Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
May 07, 2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
May 07, 2020
InDex Pharmaceuticals Holding AB (publ) Interim Report January - March 2020
May 06, 2020
Foundation for Sarcoidosis Research and University of Cincinnati Share Initial Results of COVID-19 Impact Survey
May 05, 2020
Unprecedented 3-Year Safety Data Unveiled At Digestive Disease Week (DDW) Indicates No Pattern Of Heartburn With IBgard®, An Advanced Technology Peppermint Oil, Contrary To Heartburn Issues With Older Technologies
Apr 20, 2020
Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
Apr 16, 2020
InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA
Apr 09, 2020
Crohn's & Colitis Foundation Welcomes New National Trustees
Apr 09, 2020
IFFGD's IBS Patients' Illness Experience and Unmet Needs Survey
Apr 09, 2020
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Apr 01, 2020
For IBS Awareness Month, a free trial offer to help improve IBS symptoms
Mar 26, 2020
Allergan and Bausch Health Identified as the Top Companies Driving Therapeutic Innovation in IBS
Mar 23, 2020
Prometheus Biosciences Launches Monitr(TM) COVID-19 Assistance Program (M.C.A.P.)
Mar 09, 2020
Canadians suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-D) have a new clinically proven option approved by Health Canada
Feb 25, 2020
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia
Feb 25, 2020
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
Feb 19, 2020
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
Feb 17, 2020
Irritable Bowel Syndrome Treatment Market to Reach $2.01 Bn, Globally, by 2026 at 8.2% CAGR, Says Allied Market Research
Feb 14, 2020
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)